论文部分内容阅读
该研究采用代谢组学方法对黄连、生地黄配伍前后用于Ⅱ型糖尿病治疗的配伍机制进行初步阐明。建立脂肪乳伴腹腔注射链脲佐菌素致大鼠Ⅱ型糖尿病动物模型,比较黄连、生地黄及其不同比例配伍药对的降血糖、降血脂作用。基于气相色谱-质谱联用技术分析黄连、生地黄配伍前后大鼠尿样代谢轨迹,采用主成分分析法(PCA)研究各组间的代谢物组差异。生化指标结果表明,黄连、生地黄配伍前后均能降低高血糖、高甘油三酯、高胆固醇。尿样代谢组的PCA分析结果表明,黄连组最接近于正常组,不同配伍比例黄连、生地黄组没有明显区分。确定12个差异代谢物与Ⅱ型糖尿病相关,与模型组相比较,黄连给药后对其中7个差异代谢物有显著的回调作用。黄连、生地黄及其不同配伍比例药对在治疗Ⅱ型糖尿病时,黄连起到主要作用,是君药。生地黄是臣药,辅助黄连药材发挥药效作用,本研究为阐明中药配伍机制奠定基础。
This study used metabonomics to clarify the compatibility mechanism of Coptis chinensis and Radix Rehmanniae Preparata for the treatment of type 2 diabetes. Animal models of type II diabetes induced by streptozotocin (STZ) were established by intraperitoneal injection of fat emulsion. The hypoglycemic and hypolipidemic effects of Coptis chinensis, Radix Rehmanniae Preparata and its compatibility with different proportions were compared. Based on the GC-MS technique, the metabolic trajectory of urine samples of rats before and after the administration of Coptis chinensis and Radix Rehmanniae Preparata was analyzed, and the difference of metabolites among the groups was studied by principal component analysis (PCA). Biochemical indicators showed that Coptis, Rehmannia compatibility can reduce high blood sugar, high triglycerides, high cholesterol. PCA analysis of urinary metabolites showed that the Coptis group is the closest to the normal group, there is no clear distinction between the different compatibility ratio of Coptis and Rehmannia. Twelve differential metabolites were found to be associated with type 2 diabetes. Compared with the model group, the pharmacological effects of berberine on seven different metabolites were significantly reversed. Coptis, Rehmannia and its different compatibility ratio of drugs in the treatment of type II diabetes, Coptis plays a major role, is the king medicine. Rehmanniae is a minister medicine, which aids pharmacological action of Coptis chinensis, and this study lays the foundation for clarifying compatibility mechanism of traditional Chinese medicine.